0001213900-17-001010.txt : 20170207 0001213900-17-001010.hdr.sgml : 20170207 20170207060724 ACCESSION NUMBER: 0001213900-17-001010 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170207 DATE AS OF CHANGE: 20170207 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CHINA GEWANG BIOTECHNOLOGY, INC. CENTRAL INDEX KEY: 0001489902 STANDARD INDUSTRIAL CLASSIFICATION: FOOD & KINDRED PRODUCTS [2000] IRS NUMBER: 421769584 STATE OF INCORPORATION: NV FISCAL YEAR END: 1130 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-88409 FILM NUMBER: 17577141 BUSINESS ADDRESS: STREET 1: XITA 23C STAR INTERNATIONAL, 8 JINSUI STREET 2: PEARL RIVER NEW TOWN CITY: GUANGZHOU PROVINCE STATE: F4 ZIP: 510623 BUSINESS PHONE: 020-28133873 MAIL ADDRESS: STREET 1: XITA 23C STAR INTERNATIONAL, 8 JINSUI STREET 2: PEARL RIVER NEW TOWN CITY: GUANGZHOU PROVINCE STATE: F4 ZIP: 510623 FORMER COMPANY: FORMER CONFORMED NAME: RICH STAR DEVELOPMENT Corp DATE OF NAME CHANGE: 20141203 FORMER COMPANY: FORMER CONFORMED NAME: RICH STAR DEVELOPMENT, CORP DATE OF NAME CHANGE: 20100420 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Jiang Xiuqin CENTRAL INDEX KEY: 0001684942 FILING VALUES: FORM TYPE: SC 13D MAIL ADDRESS: STREET 1: NO. 27 DONGJIN ROAD, JINGCHENG TOWN STREET 2: JINGJIANG CITY CITY: JINGSU PROVINCE STATE: F4 ZIP: 214500 SC 13D 1 sc13d0217jiang_chinagewang.htm SCHEDULE 13D

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

SCHEDULE 13D

(Rule 13d-101)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED

PURSUANT TO RULE 13d-1(a)

 

CHINA GEWANG BIOTECHNOLOGY, INC.

(Name of Issuer)

 

Common Stock

 

(Title of Class of Securities)

 

16891W107

 

(CUSIP Number)

 

XIUQIN JIANG

No. 27 Dongjin Road, Jingcheng Town

Jingjiang City, Jiangsu Province, P.R. China

86-024-2397-4663

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

August 18, 2016

 

(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(c), 13d-1(f) or 13d-1(g), check the following box.

 

 

 

 

 

 

CUSIP No. 16891W107 13D Page 2 of 4 Pages 

 

1.

NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):

 

     Xiuqin Jiang

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐

     (b) ☐

3.

SEC USE ONLY

 

4.

SOURCE OF FUNDS *  

 

     Not applicable

5.

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

 

     ☐

6.

CITIZENSHIP OR PLACE OF ORGANIZATION:

 

     P.R. China

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7.

SOLE VOTING POWER

 

 

     15,746,500

8.

SHARED VOTING POWER

 

       0
9.

SOLE DISPOSITIVE POWER

 

       15,746,500
10.

SHARED DISPOSITIVE POWER

 

       0

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

 

     15,746,500

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

 

     ☐

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11:

 

     22.7%

14.

TYPE OF REPORTING PERSON

 

     IN

 

 

 

CUSIP No. 16891W107 13D Page 3 of 4 Pages 

 

Item 1. Security and Issuer

 

The class of equity securities to which this Schedule 13D relates is the Common Stock, $0.001 par value, (the "Common Stock") of China Gewang Biotechnology, Inc., a Nevada corporation (the "Company"). The principal executive offices of the Company are located at Floor 29, No. 334, Huanshi East Road, Yuexiu District, Guangzhou City, Guangdong Province, P.R. China 510623.

 

Item 2. Identity and Background

 

a.Name: Xiuqin Jiang
b.Residence and Business Address: No. 27 Dongjin Road, Jingcheng Town, Jingjiang City, Jiangsu Province, P.R. China
c.Present employment: - Director of China Xin Fu Group Limited
d.During the past five years, Xiuqin Jiang has not been convicted in any criminal proceeding.
e.During the past five years, Xiuqin Jiang has not been a party to any civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which she was subject to any judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
f.Peoples Republic of China.

 

Item 3. Source and Amount of Funds or Other Consideration.

 

On August 18, 2016 China Xin Fu Group Limited purchased 12,775,000 shares from other shareholders. The purchase price was approximately $0.37 per share, or a total of approximately $4,725,000. Xiuqin Jiang is a director of China Xin Fu Group Limited, with voting and dispositive power over the shares.

 

Item 4. Purpose of Transaction.

 

At the time of its acquisition of the Company’s shares, as set forth in Item 3, neither China Xin Fu Group Limited nor Xiuqin Jiang had any plan or proposal which relates to or would result in any of the actions or transactions described in paragraphs (a) through (j) of the instructions to Item 4 of Schedule 13D.

 

Item 5. Interest in Securities of the Issuer.

 

(a) The information regarding share ownership by the Reporting Person provided on her cover page is incorporated here by reference.

 

(b) The information regarding share ownership by the Reporting Person provided on her cover page is incorporated here by reference.

 

(c) The Reporting Person has not effected any transactions in the shares of the Company's equity securities within the past 60 days.

 

(d) Not applicable.

 

(e) Not applicable.

 

Item 6. Contracts, Arrangements, Understandings or Relationships

 

On January 18, 2016 Xiuqin Jiang signed an Authorization that gave Han Xu voting power over shares owned by Xiuqin Jiang personally. At the present time, Xiuqin Jiang owns 2,971,500 shares personally.

 

Except as described above, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person named in Item 2 hereof and any person with respect to any securities of the Company, including but not limited to transfer or voting of any other securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies.

 

Item 7. Material to be Filed as Exhibits.

 

1.Authorization dated January 18, 2016 (translation from Mandarin Chinese).

 

 

 

CUSIP No. 16891W107 13D Page 4 of 4 Pages 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 7, 2017 /s/ Xiuqin Jiang
  Xiuqin Jiang

 

 

 

 

Exhibit 1

 

Authorization

 

There are 2 authorizing persons, totally holding 12% shares of China Gewang Biotechnology, Inc. Hereby authorize Ms Han Xu (ID NO.4401051988020223323) to represent the authorizing persons to conduct the rights and authorize her enterprise decision - making power to assume the events of the enterprise operation policy and the preparation and conduction of the investment plan.

 

Authorization duration: Taking effect since 18 January, 2016.

 

Hereby Authorize.

 

Signature of the Authorizing person (s):

 

Jun Wen (ID NO.142733196604150313), share-holding amount: 5,000,000, shareholding ratio:6.667%

 

Signature: /s/ Jun WEN                   

 

Xiuqin Jiang (ID NO. 332624196808090360), share-holding amount: 4,000,000, shareholding ratio:5.333%

 

Signature: /s/ Xiuqin JIANG          

 

Authorization Date: 18 January, 2016